程序性死亡受体1及其配体1在与自身免疫相关的眼病中的研究进展
Research advances of programmed death receptor-1 and its ligand in the pathogenesis of autoimmune-related eye diseases
程序性死亡受体1（PD-1）及其配体PD-L1作为负性共刺激因子，与机体免疫反应的调节密切相关。PD-1/PD-L1信号通路在肿瘤领域的机制研究已广泛开展，PD-1抗体刚刚获得美国FDA的批准，可在部分肿瘤的免疫治疗中应用于临床。PD-1/PD-L1系统在眼部疾病的作用机制近年来也受到广泛关注，本文旨在对PD-1/PD-L1系统在自身免疫相关的眼部疾病中的致病机制和临床治疗效果进行总结，为自身免疫相关性眼病的治疗提供新思路。
Programmed death receptor-1 (PD-1) and its ligand PD-L1, as negative co-stimulatory molecules, are closely associated with the regulation of immune responses. The PD-1/PD-L1-mediated signaling pathway has been extensively studied in tumor biology. Furthermore, PD-1 monoclonal antibodies have just been approved by the Food and Drug Administration in the US to be applied in clinical practice as an immunotherapy to certain types of tumors. In recent years, the mechanisms of action of PD-1/PD-L1 system in eye diseases have also drawn widespread attention. This review aims to summarize the pathogenic mechanisms and clinical therapeutic effects of PD-1/PD-L1 system in autoimmune-related eye diseases, providing new clues for the therapeutic modalities to the autoimmune-related ocular diseases.
郭芳、张智、漆晨、吴绵绵、张琰
眼科学肿瘤学基础医学
程序性死亡受体1（PD-1）程序性死亡受体-配体1（PD-L1）自身免疫性眼病
Programmed death receptor-1(PD-1)Programmed death-ligand 1(PD-L1)Autoimmune eye diseases
郭芳,张智,漆晨,吴绵绵,张琰.程序性死亡受体1及其配体1在与自身免疫相关的眼病中的研究进展[EB/OL].(2017-11-08)[2025-05-13].http://www.paper.edu.cn/releasepaper/content/201711-10.点此复制
评论